Physician profile
Brian Benoff
NPI 1518021716
$1,656.56
in general payments reported to CMS, 2019-2025
24 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $107 · 2021: $72.48 · 2022: $198 · 2023: $216 · 2024: $309 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $351.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $304.10 | 2019-2025 | Tezspire, Fasenra |
| Mallinckrodt Hospital Products INC. | $220.55 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.15 | 2019-2025 | Ofev |
| Harmony Biosciences LLC | $78.30 | 2020-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $63.04 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $55.60 | 2024-2025 | Inspire |
| Pfizer INC. | $52.19 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $43.53 | 2021-2024 | Dupixent |
| Axsome Therapeutics, INC. | $43.21 | 2022-2023 | Sunosi |
| Mylan Specialty L.P. | $42.31 | 2019-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $42.21 | 2019-2023 | |
| Amgen INC. | $34.71 | 2024-2025 | Tezspire |
| Mallinckrodt Enterprises LLC | $25.50 | 2019 | |
| Masimo Corporation | $25.11 | 2023 | Set and Rainbow Set |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $23.53 | 2019 | |
| Philips North America LLC | $21.32 | 2023 | |
| Viatris Specialty LLC | $18.74 | 2025 | Yupelri |
| Lilly USA, LLC | $15.91 | 2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $15.57 | 2025 | Glassia |
| Verona Pharma, INC. | $14.34 | 2025 | Ohtuvayre |
| Resmed Corp | $14.18 | 2023 | |
| Jazz Pharmaceuticals INC. | $12.57 | 2020 | |
| Insmed, INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Benoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.